|
1
|
Kumar H: Cancer and immunity: Who is
shaping whom? Int Rev Immunol. 40:317–318. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosch F and Rosich L: The contributions of
Paul Ehrlich to pharmacology: A tribute on the occasion of the
centenary of his Nobel Prize. Pharmacology. 82:171–179. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burnet M: Cancer; a biological approach.
I. The processes of control. Br Med J. 1:779–786. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kennedy LB and Salama AKS: A review of
cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the ch
aracteristics of tumor-infiltrating immune cells and their
therapeutic implications. Cell Mol Immunol. 17:807–821. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hargadon KM, Johnson CE and Williams CJ:
Immune checkpoint blockade therapy for cancer: An overview of
FDA-approved immune checkpoint inhibitors. Int Immunopharmacol.
62:29–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Leary MC, Lu X, Huang Y, Lin X, Mahmood
I, Przepiorka D, Gavin D, Lee S, Liu K, George B, et al: FDA
approval summary: Tisagenlecleucel for treatment of patients with
relapsed or refractory B-cell precursor acute lymphoblastic
leukemia. Clin Cancer Res. 25:1142–1146. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bouchkouj N, Kasamon YL, de Claro RA,
George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE and Pazdur
R: FDA approval summary: Axicabtagene ciloleucel for relapsed or
refractory large B-cell Lymphoma. Clin Cancer Res. 25:1702–1708.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheever MA and Higano CS: PROVENGE
(Sipuleucel-T) in prostate cancer: The first FDA-approved the
rapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Centers for Disease Control and Prevention
(CDC), . FDA licensure of quadrivalent human papillomavirus vaccine
(HPV4, Gardasil) for use in males and guidance from the Advisory
Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly
Rep. 59:630–632. 2010.PubMed/NCBI
|
|
12
|
Kirby T: FDA approves new upgraded
Gardasil 9. Lancet Oncol. 16:e562015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Centers for Disease Control and Prevention
(CDC), . FDA licensure of bivalent human papillomavirus vaccine
(HPV2, Cervarix) for use in females and updated HPV vaccination
recommendations from the Advisory Committee on Immunization
Practices (ACIP). MMWR Morb Mortal Wkly Rep. 59:626–629.
2010.PubMed/NCBI
|
|
14
|
Kalathil SG and Thanavala Y: High
immunosuppressive burden in cancer patients: A major hurdle for
cancer immunotherapy. Cancer Immunol Immunother. 65:813–819. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren W, Qiao Z, Wang H, Zhu L and Zhang L:
Flavonoids: Promising anticancer agents. Med Res Rev. 23:519–534.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raffa D, Maggio B, Raimondi MV, Plescia F
and Daidone G: Recent discoveries of anticancer flavonoids. Eur J
Med Chem. 142:213–228. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ravishankar D, Rajora AK, Greco F and
Osborn HM: Flavonoids as prospective compounds for anti-cancer
therapy. Int J Biochem Cell Biol. 45:2821–2831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duan N, Hu X, Zhou R, Li Y, Wu W and Liu
N: A review on dietary flavonoids as modulators of the tumor
microenvironment. Mol Nutr Food Res. 67:e22004352023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sudhakaran M, Sardesai S and Doseff AI:
Flavonoids: New frontier for immuno-regulation and breast cancer
control. Antioxidants (Basel). 8:1032019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Zhang Q, Chen Y, Liang CL, Liu H,
Qiu F and Dai Z: Antitumor effects of immunity-enhancing
traditional Chinese medicine. Biomed Pharmacother. 121:1095702020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu L, Jin Y, Song M, Zhao Y and Zhang H:
When natural compounds meet nanotechnology: Nature-Inspired
nanomedicines for cancer immunotherapy. Pharmaceutics. 14:15892022.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilky BA: Immune checkpoint inhibitors:
The linchpins of modern immunotherapy. Immunol Rev. 290:6–23. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Czajka-Francuz P, Prendes MJ, Mankan A,
Quintana Á, Pabla S, Ramkissoon S, Jensen TJ, Peiró S, Severson EA,
Achyut BR, et al: Mechanisms of immune modulation in the tumor
microenvironment and impl ications for targeted therapy. Front
Oncol. 13:12006462023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Currenti J, Mishra A, Wallace M, George J
and Sharma A: Immunosuppressive mechanisms of oncofetal
reprogramming in the tumor microenvironment: Implications in
immunotherapy response. Biochem Soc Trans. 51:597–612.
2023.PubMed/NCBI
|
|
25
|
Li Y, Xiang S, Pan W, Wang J, Zhan H and
Liu S: Targeting tumor immunosuppressive microenvironment for
pancreatic cancer immunotherapy: Current research and future
perspective. Front Oncol. 13:11668602023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kimura S, Nanbu U, Noguchi H, Harada Y,
Kumamoto K, Sasaguri Y and Nakayama T: Macrophage CCL22 expression
in the tumor microenvironment and implications for survival in
patients with squamous cell carcinoma of the tongue. J Oral Pathol
Med. 48:677–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li
CX, Ng KT, Forbes SJ, Guan XY, Poon RT, et al: Alternatively
activated (M2) macrophages promote tumour growth and inv asiveness
in hepatocellular carcinoma. J Hepatol. 62:607–616. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tie Y, Tang F, Wei YQ and Wei XW:
Immunosuppressive cells in cancer: Mechanisms and potential
therapeuti c targets. J Hematol Oncol. 15:612022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khazaie K and von Boehmer H: The impact of
CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and
cancer. Semin Cancer Biol. 16:124–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rotte A: Combination of CTLA-4 and PD-1
blockers for treatment of cancer. J Exp Clin Cancer Res.
38:2552019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Dai Z, Wu W, Wang Z, Zhang N,
Zhang L, Zeng WJ, Liu Z and Cheng Q: Regulatory mechanisms of
immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer
Res. 40:1842021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wojtukiewicz MZ, Rek MM, Karpowicz K,
Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P,
Tucker SC and Honn KV: Inhibitors of immune checkpoints-PD-1,
PD-L1, CTLA-4-new opportunities for cancer patients and a new
challenge for internists and general practitioners. Cancer
Metastasis Rev. 40:949–982. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zak KM, Grudnik P, Magiera K, Dömling A,
Dubin G and Holak TA: Structural biology of the immune checkpoint
receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 25:1163–1174.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kennedy A, Waters E, Rowshanravan B, Hinze
C, Williams C, Janman D, Fox TA, Booth C, Pesenacker AM, Halliday
N, et al: Differences in CD80 and CD86 transendocytosis reveal CD86
as a key target for CTLA-4 immune regulation. Nat Immunol.
23:1365–1378. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chikuma S: CTLA-4, an essential
immune-checkpoint for T-cell activation. Curr Top Microbiol
Immunol. 410:99–126. 2017.PubMed/NCBI
|
|
37
|
Goldberg MV and Drake CG: LAG-3 in cancer
immunotherapy. Curr Top Microbiol Immunol. 344:269–278.
2011.PubMed/NCBI
|
|
38
|
Chauvin JM and Zarour HM: TIGIT in cancer
immunotherapy. J Immunother Cancer. 8:e0009572020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang W, Chen J, Ji T and Cong X: TIGIT, a
novel immune checkpoint therapy for melanoma. Cell Death Dis.
14:4662023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang R, Rangachari M and Kuchroo VK:
Tim-3: A co-receptor with diverse roles in T cell exhaustion and
tolerance. Semin Immunol. 42:1013022019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kane LP: Regulation of Tim-3 function by
binding to phosphatidylserine. Biochem J. 478:3999–4004. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Haist M, Stege H, Grabbe S and Bros M: The
functional crosstalk between myeloid-derived suppressor cells and
regulatory T cells within the immunosuppressive tumor
microenvironment. Cancers (Basel). 13:2102021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu C, Redd PS, Lee JR, Savage N and Liu K:
The expression profiles and regulation of PD-L1 in tumor-induced
myeloid-derived suppressor cells. Oncoimmunology. 5:e12471352016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sasidharan Nair V and Elkord E: Immune
checkpoint inhibitors in cancer therapy: A focus on T-regulatory
cells. Immunol Cell Biol. 96:21–33. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Malinga NZ, Siwele SC, Steel HC, Kwofie
LLI, Meyer PWA, Smit T, Anderson R, Rapoport BL and Kgokolo MCM:
Systemic levels of the soluble co-inhibitory immune checkpoints,
CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal
cell carcinoma. Transl Oncol. 19:1013842022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu Y and Cao X: Immunosuppressive cells
in tumor immune escape and metastasis. J Mol Med (Berl).
94:509–522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Martínez G, Mijares MR and De Sanctis JB:
Effects of flavonoids and its derivatives on immune cell responses.
Recent Pat Inflamm Allergy Drug Discov. 13:84–104. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Taylor PR, Martinez-Pomares L, Stacey M,
Lin HH, Brown GD and Gordon S: Macrophage receptors and immune
recognition. Annu Rev Immunol. 23:901–944. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nikitina E, Larionova I, Choinzonov E and
Kzhyshkowska J: Monocytes and macrophages as viral targets and
reservoirs. Int J Mol Sci. 19:28212018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wynn TA, Chawla A and Pollard JW:
Macrophage biology in development, homeostasis and disease. Nature.
496:445–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Locati M, Curtale G and Mantovani A:
Diversity, mechanisms, and significance of macrophage plasticity.
Annu Rev Pathol. 15:123–147. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aras S and Zaidi MR: TAMeless traitors:
Macrophages in cancer progression and metastasis. Br J Cancer.
117:1583–1591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shen Y, Chen JX, Li M, Xiang Z, Wu J and
Wang YJ: Role of tumor-associated macrophages in common digestive
system malign ant tumors. World J Gastrointest Oncol. 15:596–616.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Khan SU, Khan MU, Azhar Ud Din M, Khan IM,
Khan MI, Bungau S and Hassan SSU: Reprogramming tumor-associated
macrophages as a unique approach to target tumor immunotherapy.
Front Immunol. 14:11664872023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Choi HJ, Choi HJ, Chung TW and Ha KT:
Luteolin inhibits recruitment of monocytes and migration of Lewis
lung carcinoma cells by suppressing chemokine (C-C motif) ligand 2
express ion in tumor-associated macrophage. Biochem Biophys Res
Commun. 470:101–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tripathi DK, Nagar N, Kumar V, Joshi N,
Roy P and Poluri KM: Gallate moiety of catechin is essential for
inhibiting CCL2 chemokine-mediated monocyte recruitment. J Agric
Food Chem. 71:4990–5005. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li C, Xu Y, Zhang J, Zhang Y, He W, Ju J,
Wu Y and Wang Y: The effect of resveratrol, curcumin and quercetin
combination on immuno-suppression of tumor microenvironment for
breast tumor-bearing mice. Sci Rep. 13:132782023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jiang YX, Chen Y, Yang Y, Chen XX and
Zhang DD: Screening Five Qi-Tonifying Herbs on M2 phenotype
macrophages. Evid Based Complement Alternat Med. 2019:95493152019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhao H, Zhang X, Chen X, Li Y, Ke Z, Tang
T, Chai H, Guo AM, Chen H and Yang J: Isoliquiritigenin, a
flavonoid from licorice, blocks M2 macrophage polarization in
colitis-associated tumorigenesis through downregulating PGE2 and
IL-6. Toxicol Appl Pharmacol. 279:311–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
He S, Wang S, Liu S, Li Z, Liu X and Wu J:
Baicalein potentiated M1 macrophage polarization in cancer through
Tar geting PI3Kγ/NF-κB signaling. Front Pharmacol. 12:7438372021.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tan HY, Wang N, Man K, Tsao SW, Che CM and
Feng Y: Autophagy-induced RelB/p52 activation mediates
tumour-associated macrophage repolarisation and suppression of
hepatocellular carcinoma by natural compound baicalin. Cell Death
Dis. 6:e19422015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mukherjee S, Hussaini R, White R, Atwi D,
Fried A, Sampat S, Piao L, Pan Q and Banerjee P: TriCurin, a
synergistic formulation of curcumin, resveratrol, and epicatechin
gallate, repolarizes tumor-associated macrophages and triggers an
immune response to cause suppression of HPV+ tumors. Cancer Immunol
Immunother. 67:761–774. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fonseca M, Macedo AS, Lima SAC, Reis S,
Soares R and Fonte P: Evaluation of the antitumour and
antiproliferative effect of xanthohumol-loaded PLGA nanoparticles
on melanoma. Materials (Basel). 14:64212021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sulaiman GM, Waheeb HM, Jabir MS, Khazaal
SH, Dewir YH and Naidoo Y: Hesperidin loaded on gold nanoparticles
as a drug delivery system for a successful biocompatible,
anti-cancer, anti-inflammatory and phagocytosis inducer model. Sci
Rep. 10:93622020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dickerhof N, Magon NJ, Tyndall JDA, Kettle
AJ and Hampton MB: Potent inhibition of macrophage migration
inhibitory factor (MIF) by m yeloperoxidase-dependent oxidation of
epicatechins. Biochem J. 462:303–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sakai M, Ohnishi K, Masuda M, Ohminami H,
Yamanaka-Okumura H, Hara T and Taketani Y: Isorhamnetin, a
3′-methoxylated flavonol, enhances the lysosomal prote olysis in
J774.1 murine macrophages in a TFEB-independent manner. Biosci
Biotechnol Biochem. 84:1221–1231. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Greten TF, Manns MP and Korangy F: Myeloid
derived suppressor cells in human diseases. Int Immunopharmacol.
11:802–807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li BH, Garstka MA and Li ZF: Chemokines
and their receptors promoting the recruitment of myeloid-de rived
suppressor cells into the tumor. Mol Immunol. 117:201–215. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ozga AJ, Chow MT and Luster AD: Chemokines
and the immune response to cancer. Immunity. 54:859–874. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lindau D, Gielen P, Kroesen M, Wesseling P
and Adema GJ: The immunosuppressive tumour network: Myeloid-derived
suppressor cells, regulatory T cells and natural killer T cells.
Immunology. 138:105–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Law AMK, Valdes-Mora F and Gallego-Ortega
D: Myeloid-derived suppressor cells as a therapeutic target for
cancer. Cells. 9:5612020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ohl K and Tenbrock K: Reactive oxygen
species as regulators of MDSC-mediated immune suppression. Front
Immunol. 9:24992018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hatziioannou A, Alissafi T and Verginis P:
Myeloid-derived suppressor cells and T regulatory cells in tumors:
Unr aveling the dark side of the force. J Leukoc Biol. 102:407–421.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Bauer D, Redmon N, Mazzio E and Soliman
KF: Apigenin inhibits TNFα/IL-1α-induced CCL2 release through
IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells.
PLoS One. 12:e01755582017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Xu P, Yan F, Zhao Y, Chen X, Sun S, Wang Y
and Ying L: Green tea polyphenol EGCG Attenuates MDSCs-mediated
immunosuppression through canonical and non-canonical pathways in a
4T1 murine breast cancer model. Nutrients. 12:10422020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wu T, Liu W, Guo W and Zhu X: Silymarin
suppressed lung cancer growth in mice via inhibiting
myeloid-derived suppressor cells. Biomed Pharmacother. 81:460–467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Guo J, Shen Y, Hu S, Rui T, Liu J and Yuan
Y: Neobavaisoflavone inhibits antitumor immunosuppression via
myeloid-der ived suppressor cells. Int Immunopharmacol.
111:1091032022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhou J, Wu J, Chen X, Fortenbery N,
Eksioglu E, Kodumudi KN, Pk EB, Dong J, Djeu JY and Wei S: Icariin
and its derivative, ICT, exert anti-inflammatory, anti-tumor e
ffects, and modulate myeloid derived suppressive cells (MDSCs)
functio ns. Int Immunopharmacol. 11:890–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li Y, Yang R, Huang X, Chen C, Dou D, Wang
Q, Wu X, Liu H and Sun T: Chrysin targets myeloid-derived
suppressor cells and enhances tumour response to anti-PD-1
immunotherapy. Clin Transl Med. 12:e10192022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Sugiyama D, Hinohara K and Nishikawa H:
Significance of regulatory T cells in cancer immunology and
immunotherapy. Exp Dermatol. 32:256–263. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Tay C, Tanaka A and Sakaguchi S:
Tumor-infiltrating regulatory T cells as targets of cancer
immunotherapy. Cancer Cell. 41:450–465. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Moreau JM, Velegraki M, Bolyard C,
Rosenblum MD and Li Z: Transforming growth factor-β1 in regulatory
T cell biology. Sci Immunol. 7:eabi46132022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Beissert S, Schwarz A and Schwarz T:
Regulatory T cells. J Invest Dermatol. 126:15–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen X, Du Y, Lin X, Qian Y, Zhou T and
Huang Z: CD4+CD25+ regulatory T cells in tumor immunity. Int
Immunopharmacol. 34:244–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hosseinalizadeh H, Rabiee F, Eghbalifard
N, Rajabi H, Klionsky DJ and Rezaee A: Regulating the regulatory T
cells as cell therapies in autoimmunity an d cancer. Front Med
(Lausanne). 10:12442982023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wilke CM, Wu K, Zhao E, Wang G and Zou W:
Prognostic significance of regulatory T cells in tumor. Int J
Cancer. 127:748–758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Han XY, Xu N, Yuan JF, Wu H, Shi HL, Yang
L and Wu XJ: Total flavonoids of astragalus inhibit activated
CD4[Formula: See text] T cells and regulate differentiation of
Th17/Th1/Treg cells in exper imental autoimmune encephalomyelitis
mice by JAK/STAT and NF[Formula: See text]B signaling pathways. Am
J Chin Med. 51:1233–1248. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Fujiki T, Shinozaki R, Udono M and
Katakura Y: Identification and functional evaluation of polyphenols
that induce re gulatory T cells. Nutrients. 14:28622022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Dandawate S, Williams L, Joshee N, Rimando
AM, Mittal S, Thakur A, Lum LG and Parajuli P: Scutellaria extract
and wogonin inhibit tumor-mediated induction of T(reg) cells via
inhibition of TGF-β1 activity. Cancer Immunol Immunother.
61:701–711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Du G, Jin L, Han X, Song Z, Zhang H and
Liang W: Naringenin: A potential immunomodulator for inhibiting
lung fibrosis a nd metastasis. Cancer Res. 69:3205–3212. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Feng Z, Hao W, Lin X, Fan D and Zhou J:
Antitumor activity of total flavonoids from Tetrastigma hemsleyanum
Diels et Gilg is associated with the inhibition of regulatory T
cells in mice. Onco Targets Ther. 7:947–956. 2014.PubMed/NCBI
|
|
94
|
Chen S, Li R, Chen Y, Chou CK, Zhang Z,
Yang Y, Liao P, Wang Q and Chen X: Scutellarin enhances anti-tumor
immune responses by reducing TNFR2-expressing CD4+Foxp3+ regulatory
T cells. Biomed Pharmacother. 151:1131872022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Gardner A and Ruffell B: Dendritic cells
and cancer immunity. Trends Immunol. 37:855–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Del Prete A, Salvi V, Soriani A,
Laffranchi M, Sozio F, Bosisio D and Sozzani S: Dendritic cell
subsets in cancer immunity and tumor antigen sensing. Cell Mol
Immunol. 20:432–447. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Xiao Z, Wang R, Wang X, Yang H, Dong J, He
X, Yang Y, Guo J, Cui J and Zhou Z: Impaired function of dendritic
cells within the tumor microenvironment. Front Immunol.
14:12136292023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wesa AK and Storkus WJ: Killer dendritic
cells: Mechanisms of action and therapeutic implicati ons for
cancer. Cell Death Differ. 15:51–57. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chauvin C and Josien R: Dendritic cells as
killers: Mechanistic aspects and potential roles. J Immunol.
181:11–16. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
LaCasse CJ, Janikashvili N, Larmonier CB,
Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M,
Bonnotte B, et al: Th-1 lymphocytes induce dendritic cell tumor
killing activity by an IF N-γ-dependent mechanism. J Immunol.
187:6310–6317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Mittal SK and Roche PA: Suppression of
antigen presentation by IL-10. Curr Opin Immunol. 34:22–27. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xiao W, Wu K, Yin M, Han S, Ding Y, Qiao
A, Lu G, Deng B, Bo P and Gong W: Wogonin inhibits tumor-derived
regulatory molecules by suppressing STA T3 signaling to promote
tumor immunity. J Immunother. 38:167–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yang Y, Li XJ, Chen Z, Zhu XX, Wang J,
Zhang LB, Qiang L, Ma YJ, Li ZY, Guo QL and You QD: Wogonin induced
calreticulin/annexin A1 exposure dictates the immunogenicity of
cancer cells in a PERK/AKT dependent manner. PLoS One.
7:e508112012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Bandyopadhyay S, Romero JR and
Chattopadhyay N: Kaempferol and quercetin stimulate
granulocyte-macrophage colony-stimulating factor secretion in human
prostate cancer cells. Mol Cell Endocrinol. 287:57–64. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wang L, Zeng W, Wang L, Wang Z, Yin X, Qin
Y, Zhang F, Zhang C and Liang W: Naringenin enhances the antitumor
effect of therapeutic vaccines by promoting antigen
cross-presentation. J Immunol. 204:622–631. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Liu BC, Qiu Y, Zhao RD, Han X, Yun FY and
Tui X: Digital gene expression profiling of dendritic cells treated
with Seabuckthorn favones. Chin J Microbiol Immunol. 37:840–848.
2017.
|
|
107
|
Verna G, Liso M, Cavalcanti E, Bianco G,
Di Sarno V, Santino A, Campiglia P and Chieppa M: Quercetin
administration suppresses the cytokine storm in myeloid and
plasmacytoid dendritic cells. Int J Mol Sci. 22:83492021.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Sawicki MW, Dimasi N, Natarajan K, Wang J,
Margulies DH and Mariuzza RA: Structural basis of MHC class I
recognition by natural killer cell receptors. Immunol Rev.
181:52–65. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cerwenka A and Lanier LL: Ligands for
natural killer cell receptors: Redundancy or specificity. Immunol
Rev. 181:158–169. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Gianchecchi E, Delfino DV and Fierabracci
A: Natural killer cells: Potential biomarkers and therapeutic
target in A utoimmune diseases? Front Immunol. 12:6168532021.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Portale F and Di Mitri D: NK cells in
cancer: Mechanisms of dysfunction and therapeutic potentia l. Int J
Mol Sci. 24:95212023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Prager I and Watzl C: Mechanisms of
natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol.
105:1319–1329. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Alspach E, Lussier DM and Schreiber RD:
Interferon γ and its important roles in promoting and inhibiting
spontaneous and therapeutic cancer immunity. Cold Spring Harb
Perspect Biol. 11:a0284802019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Boehm U, Klamp T, Groot M and Howard JC:
Cellular responses to interferon-gamma. Annu Rev Immunol.
15:749–795. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Lian GY, Wang QM, Tang PM, Zhou S, Huang
XR and Lan HY: Combination of asiatic acid and naringenin modulates
NK cell anti-canc er immunity by rebalancing Smad3/Smad7 signaling.
Mol Ther. 26:2255–2266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Feng YB, Chen L, Chen FX, Yang Y, Chen GH,
Zhou ZH and Xu CF: Immunopotentiation effects of apigenin on NK
cell proliferation and killing pancreatic cancer cells. Int J
Immunopathol Pharmacol. 37:39463202311611742023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lee HH and Cho H: Apigenin increases
natural killer cytotoxicity to human hepatocellular carcinoma
expressing HIF-1α through high interaction of CD95/CD95L. J
Microbiol Biotechnol. 32:397–404. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Pathni A, Özçelikkale A, Rey-Suarez I, Li
L, Davis S, Rogers N, Xiao Z and Upadhyaya A: Cytotoxic T
lymphocyte activation signals modulate cytoskeletal dynamics and
mechanical force generation. Front Immunol. 13:7798882022.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Hay ZLZ and Slansky JE: Granzymes: The
molecular executors of immune-mediated cytotoxicity. Int J Mol Sci.
23:18332022. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Weigelin B and Friedl P: T cell-mediated
additive cytotoxicity-death by multiple bullets. Trends Cancer.
8:980–987. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zeytun A, Hassuneh M, Nagarkatti M and
Nagarkatti PS: Fas-Fas ligand-based interactions between tumor
cells and tumor-specif ic cytotoxic T lymphocytes: A lethal two-way
street. Blood. 90:1952–1959. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K,
Kagamu H, Suzuki E, Gejyo F, Hamada H and Arakawa M: Successful
adoptive immunotherapy of murine poorly immunogenic tumor with
specific effector cells generated from gene-modified tumor-primed
lymph node cells. J Immunol. 162:3574–3582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Péguillet I, Milder M, Louis D,
Vincent-Salomon A, Dorval T, Piperno-Neumann S, Scholl SM and Lantz
O: High numbers of differentiated effector CD4 T cells are found in
patients with cancer and correlate with clinical response after
neoadjuvant therapy of breast cancer. Cancer Res. 74:2204–2216.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Magombedze G, Reddy PBJ, Eda S and Ganusov
VV: Cellular and population plasticity of helper CD4(+) T cell
responses. Front Physiol. 4:2062013. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang LX, Shu S, Disis ML and Plautz GE:
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T
effector cells (TEs) combined with CD8+ TEs provides intratumoral
TE prolifera tion and synergistic antitumor response. Blood.
109:4865–4876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Bourgeois C, Rocha B and Tanchot C: A role
for CD40 expression on CD8+ T cells in the generation of CD8+ T
cell memory. Science. 297:2060–2063. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X,
Wu R, Lv Y and Dong J: Baicalein and baicalin promote antitumor
immunity by suppressing PD-L1 expression in hepatocellular
carcinoma cells. Int Immunopharmacol. 75:1058242019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Kawaguchi S, Kawahara K, Fujiwara Y,
Ohnishi K, Pan C, Yano H, Hirosue A, Nagata M, Hirayama M, Sakata
J, et al: Naringenin potentiates anti-tumor immunity against oral
cancer by inducing lymph node CD169-positive macrophage activation
and cytotoxic T cell infiltration. Cancer Immunol Immunother.
71:2127–2139. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Maatouk M, Elgueder D, Mustapha N, Chaaban
H, Bzéouich IM, Loannou I, Kilani S, Ghoul M, Ghedira K and
Chekir-Ghedira L: Effect of heated naringenin on immunomodulatory
properties and cellular antioxidant activity. Cell Stress
Chaperones. 21:1101–1109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Pfarr K, Danciu C, Arlt O, Neske C,
Dehelean C, Pfeilschifter JM and Radeke HH: Simultaneous and dose
dependent melanoma cytotoxic and immune stimulat ory activity of
betulin. PLoS One. 10:e01188022015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Sassi A, Maatouk M, El Gueder D, Bzéouich
IM, Abdelkefi-Ben Hatira S, Jemni-Yacoub S, Ghedira K and
Chekir-Ghedira L: Chrysin, a natural and biologically active
flavonoid suppresses tumor growth of mouse B16F10 melanoma cells:
In vitro and in vivo study. Chem Biol Interact. 283:10–19. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sassi A, Mokdad Bzéouich I, Mustapha N,
Maatouk M, Ghedira K and Chekir-Ghedira L: Immunomodulatory
potential of hesperetin and chrysin through the cellular and
humoral response. Eur J Pharmacol. 812:91–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yonekawa M, Shimizu M, Kaneko A, Matsumura
J and Takahashi H: Suppression of R5-type of HIV-1 in
CD4+ NKT cells by Vδ1+ T cells activated by
flavonoid glycosides, hesperidin and linarin. Sci Rep. 9:75062019.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Bruni E, Cimino MM, Donadon M, Carriero R,
Terzoli S, Piazza R, Ravens S, Prinz I, Cazzetta V, Marzano P, et
al: Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of
patients with metastatic colorectal cancer and limit tumor
progression. J Immunother Cancer. 10:e0045792022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Wu Y, Biswas D, Usaite I, Angelova M,
Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J, Morton C, Joseph
M, et al: A local human Vδ1 T cell population is associated with
survival in non small-cell lung cancer. Nat Cancer. 3:696–709.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Tang H, Liu Y, Wang C, Zheng H, Chen Y,
Liu W, Chen X, Zhang J, Chen H, Yang Y and Yang J: Inhibition of
COX-2 and EGFR by melafolone improves Anti-PD-1 therapy through
vascular normalization and PD-L1 downregulation in lung cancer. J
Pharmacol Exp Ther. 368:401–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Tian L, Wang S, Jiang S, Liu Z, Wan X,
Yang C, Zhang L, Zheng Z, Wang B and Li L: Luteolin as an adjuvant
effectively enhances CTL anti-tumor response in B16F10 mouse model.
Int Immunopharmacol. 94:1074412021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhang W, Pan Y, Gou P, Zhou C, Ma L, Liu
Q, Du Y, Yang J and Wang Q: Effect of xanthohumol on Th1/Th2
balance in a breast cancer mouse model. Oncol Rep. 39:280–288.
2018.PubMed/NCBI
|
|
139
|
Xu L, Zhang Y, Tian K, Chen X, Zhang R, Mu
X, Wu Y, Wang D, Wang S, Liu F, et al: Apigenin suppresses PD-L1
expression in melanoma and host dendritic ce lls to elicit
synergistic therapeutic effects. J Exp Clin Cancer Res. 37:2612018.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Coombs MRP, Harrison ME and Hoskin DW:
Apigenin inhibits the inducible expression of programmed death
ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett.
380:424–433. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR,
Zhang YZ, Huang JM, Huang M, Xie C, Liu P, et al: Luteolin and its
derivative apigenin suppress the inducible PD-L1 expr ession to
improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer
Lett. 515:36–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Li Z, Gao WQ, Wang P, Wang TQ, Xu WC, Zhu
XY and Liu H: Pentamethylquercetin inhibits hepatocellular
carcinoma progression and adipocytes-induced PD-L1 expression via
IFN-γ signaling. Curr Cancer Drug Targets. 20:868–874. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Sp N, Kang DY, Lee JM and Jang KJ:
Mechanistic insights of anti-immune evasion by nobiletin through
regul ating miR-197/STAT3/PD-L1 signaling in non-small cell lung
cancer (NSC LC) cells. Int J Mol Sci. 22:98432021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Chen YC, He XL, Qi L, Shi W, Yuan LW,
Huang MY, Xu YL, Chen X, Gu L, Zhang LL and Lu JJ: Myricetin
inhibits interferon-γ-induced PD-L1 and IDO1 expression in l ung
cancer cells. Biochem Pharmacol. 197:1149402022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zhong Y, Li MY, Han L, Tai Y, Cao S, Li J,
Zhao H, Wang R, Lv B, Shan Z, et al: Galangin inhibits programmed
cell death-ligand 1 expression by suppres sing STAT3 and MYC and
enhances T cell tumor-killing activity. Phytomedicine.
116:1548772023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kongtawelert P, Wudtiwai B, Shwe TH,
Pothacharoen P and Phitak T: Inhibitory effect of hesperidin on the
expression of programmed death ligand (PD-L1) in breast cancer.
Molecules. 25:2522020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Rong W, Wan N, Zheng X, Shi G, Jiang C,
Pan K, Gao M, Yin Z, Gao ZJ and Zhang J: Chrysin inhibits
hepatocellular carcinoma progression through suppressing programmed
death ligand 1 expression. Phytomedicine. 95:1538672022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Mo D, Zhu H, Wang J, Hao H, Guo Y, Wang J,
Han X, Zou L, Li Z, Yao H, et al: Icaritin inhibits PD-L1
expression by Targeting Protein IκB Kinase α. Eur J Immunol.
51:978–988. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Hao H, Zhang Q, Zhu H, Wen Y, Qiu D, Xiong
J, Fu X, Wu Y, Meng K and Li J: Icaritin promotes tumor T-cell
infiltration and induces antitumor immu nity in mice. Eur J
Immunol. 49:2235–2244. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Dongye Z, Wu X, Wen Y, Ding X, Wang C,
Zhao T, Li J and Wu Y: Icaritin and intratumoral injection of CpG
treatment synergistically promote T cell infiltration and antitumor
immune response in mice. Int Immunopharmacol. 111:1090932022.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yuan LW, Jiang XM, Xu YL, Huang MY, Chen
YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y and Lu JJ: Licochalcone A
inhibits interferon-gamma-induced programmed death-ligand 1 in lung
cancer cells. Phytomedicine. 80:1533942021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Mei C, Zhang X, Zhi Y, Liang Z, Xu H, Liu
Z, Liu Y, Lyu Y and Wang H: Isorhamnetin regulates programmed death
ligand-1 expression by suppressing the EGFR-STAT3 signaling pathway
in canine mammary tumors. Int J Mol Sci. 25:6702024. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Li L, Zhang Y, Hu W, Zou F, Ning J, Rao T,
Ruan Y, Yu W and Cheng F: MTHFD2 promotes PD-L1 expression via
activation of the JAK/STAT signal ling pathway in bladder cancer. J
Cell Mol Med. 27:2922–2936. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Iwasaki T, Kohashi K, Toda Y, Ishihara S,
Yamada Y and Oda Y: Association of PD-L1 and IDO1 expression with
JAK-STAT pathway activation in soft-tissue leiomyosarcoma. J Cancer
Res Clin Oncol. 147:1451–1463. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Doi T, Ishikawa T, Okayama T, Oka K,
Mizushima K, Yasuda T, Sakamoto N, Katada K, Kamada K, Uchiyama K,
et al: The JAK/STAT pathway is involved in the upregulation of
PD-L1 expressi on in pancreatic cancer cell lines. Oncol Rep.
37:1545–1554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Antonangeli F, Natalini A, Garassino MC,
Sica A, Santoni A and Di Rosa F: Regulation of PD-L1 expression by
NF-κB in cancer. Front Immunol. 11:5846262020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Betzler AC, Theodoraki MN, Schuler PJ,
Döscher J, Laban S, Hoffmann TK and Brunner C: NF-κB and its role
in checkpoint control. Int J Mol Sci. 21:39492020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Li C, Yang F, Wang R, Li W, Maskey N,
Zhang W, Guo Y, Liu S, Wang H and Yao X: CALD1 promotes the
expression of PD-L1 in bladder cancer via the JAK/S TAT signaling
pathway. Ann Transl Med. 9:14412021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Wang Y, Zhang X, Xie X, Chen W, Li M, Diao
D and Dang C: Obesity and metabolic syndrome related macrophage
promotes PD-L1 expre ssion in TNBC through IL6/JAK/STAT pathway and
can be reversed by telm isartan. Cancer Biol Ther. 21:1179–1190.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Padmanabhan S, Gaire B, de Leon D, Vancura
A and Vancurova I: Interferon-γ induces PD-L1 expression in ovarian
cancer cells by JAK/STAT1 signaling. FASEB J 34 (S1). 1. 2020.
View Article : Google Scholar
|
|
161
|
Liu M, Wei F, Wang J, Yu W, Shen M, Liu T,
Zhang D, Wang Y, Ren X and Sun Q: Myeloid-derived suppressor cells
regulate the immunosuppressive functions of
PD-1−PD-L1+ Bregs through
PD-L1/PI3K/AKT/NF-κB axis in breast cancer. Cell Death Dis.
12:4652021. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Hu M, Yang J, Qu L, Deng X, Duan Z, Fu R,
Liang L and Fan D: Ginsenoside Rk1 induces apoptosis and
downregulates the expression of PD-L1 by targeting the NF-κB
pathway in lung adenocarcinoma. Food Funct. 11:456–471. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Liu S, Han Z, Trivett AL, Lin H, Hannifin
S, Yang D and Oppenheim JJ: Cryptotanshinone has curative dual
anti-proliferative and immunotherapeutic effects on mouse Lewis
lung carcinoma. Cancer Immunol Immunother. 68:1059–1071. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wu R, Xiong J, Zhou T, Zhang Z, Huang Z,
Tian S and Wang Y: Quercetin/Anti-PD-1 antibody combination therapy
regulates the gut microbiota, impacts macrophage immunity and
reshapes the hepatocellular carcinoma tumor microenvironment. Front
Biosci (Landmark Ed). 28:3272023. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Cuzick J: Preventive therapy for cancer.
Lancet Oncol. 18:e472–e482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Buonaguro L, Petrizzo A, Tornesello ML and
Buonaguro FM: Translating tumor antigens into cancer vaccines. Clin
Vaccine Immunol. 18:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Harper DM: Currently approved prophylactic
HPV vaccines. Expert Rev Vaccines. 8:1663–1679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Cheng L, Wang Y and Du J: Human
papillomavirus vaccines: An updated review. Vaccines (Basel).
8:3912020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Brower V: Approval of provenge seen as
first step for cancer treatment vaccines. J Natl Cancer Inst.
102:1108–1110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Ogi C and Aruga A: Clinical evaluation of
therapeutic cancer vaccines. Hum Vaccin Immunother. 9:1049–1057.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Pao SC, Chu MT and Hung SI: Therapeutic
vaccines targeting neoantigens to induce T-cell immunity against
cancers. Pharmaceutics. 14:8672022. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Cho HI and Celis E: Optimized peptide
vaccines eliciting extensive CD8 T-cell responses with therapeutic
antitumor effects. Cancer Res. 69:9012–9019. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Stegmann T, Wiekmeijer AS, Kwappenberg K,
van Duikeren S, Bhoelan F, Bemelman D, Beenakker TJM, Krebber WJ,
Arens R and Melief CJM: Enhanced HPV16 E6/E7+ tumor eradication via
induction of tumor-specific T cells by therapeutic vaccination with
virosomes presenting synthetic long peptides. Cancer Immunol
Immunother. 72:2851–2864. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Fucikova J, Kepp O, Kasikova L, Petroni G,
Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G and Galluzzi L:
Detection of immunogenic cell death and its relevance for cancer
therapy. Cell Death Dis. 11:10132020. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Radogna F and Diederich M: Stress-induced
cellular responses in immunogenic cell death: Implications for
cancer immunotherapy. Biochem Pharmacol. 153:12–23. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Ahmed A and Tait SWG: Targeting
immunogenic cell death in cancer. Mol Oncol. 14:2994–3006. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Patra S, Roy PK, Dey A and Mandal M:
Impact of HMGB1 on cancer development and therapeutic insights
focused on CNS malignancy. Biochim Biophys Acta Rev Cancer.
1879:1891052024. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Patidar A, Selvaraj S, Sarode A, Chauhan
P, Chattopadhyay D and Saha B: DAMP-TLR-cytokine axis dictates the
fate of tumor. Cytokine. 104:114–123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Nace G, Evankovich J, Eid R and Tsung A:
Dendritic cells and damage-associated molecular patterns:
Endogenous danger signals linking innate and adaptive immunity. J
Innate Immun. 4:6–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Lee SM, Kim P, You J and Kim EH: Role of
damage-associated molecular pattern/cell death pathways in
vaccine-induced immunity. Viruses. 13:23402021. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ,
Kang R, Lotze MT and Tang D: Strange attractors: DAMPs and
autophagy link tumor cell death and immunity. Cell Death Dis.
4:e9662013. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Woo SR, Corrales L and Gajewski TF: Innate
immune recognition of cancer. Annu Rev Immunol. 33:445–474. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Tsuchiya K: Switching from apoptosis to
pyroptosis: Gasdermin-elicited inflammation and antitumor immunity.
Int J Mol Sci. 22:4262021. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Pandolfi F, Altamura S, Frosali S and
Conti P: Key role of DAMP in inflammation, cancer, and tissue
repair. Clin Ther. 38:1017–1028. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Helm O, Held-Feindt J, Grage-Griebenow E,
Reiling N, Ungefroren H, Vogel I, Krüger U, Becker T, Ebsen M,
Röcken C, et al: Tumor-associated macrophages exhibit pro-and
anti-inflammatory properties by which they impact on pancreatic
tumorigenesis. Int J Cancer. 135:843–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Shalapour S and Karin M: Pas de deux:
Control of anti-tumor immunity by cancer-associated inflammation.
Immunity. 51:15–26. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Galluzzi L, Vacchelli E, Bravo-San Pedro
JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado
JP, Agostinis P, et al: Classification of current anticancer
immunotherapies. Oncotarget. 5:12472–12508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Jafari S, Heydarian S, Lai R, Mehdizadeh
Aghdam E and Molavi O: Silibinin induces immunogenic cell death in
cancer cells and enhances the induced immunogenicity by
chemotherapy. Bioimpacts. 13:51–61. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Xia L, Xu X, Li M, Zhang X and Cao F:
Afzelin induces immunogenic cell death against lung cancer by
targeting NQO2. BMC Complement Med Ther. 23:3812023. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Zhu MY, Wang T, Wang HD, Wang HZ, Chen HY,
Zhang S, Guo YJ, Li H and Hui H: LW-213 induces immunogenic tumor
cell death via ER stress mediated by lysosomal TRPML1. Cancer Lett.
577:2164352023. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Li L, Zou Y, Wang L, Yang L, Li Y, Liao A,
Chen Z, Yu Z, Guo J and Han S: Nanodelivery of scutellarin induces
immunogenic cell death for treating hepatocellular carcinoma. Int J
Pharm. 642:1231142023. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Xiao Y, Yao W, Lin M, Huang W, Li B, Peng
B, Ma Q, Zhou X and Liang M: Icaritin-loaded PLGA nanoparticles
activate immunogenic cell death and facilitate tumor recruitment in
mice with gastric cancer. Drug Deliv. 29:1712–1725. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Zhang J, Shen L, Li X, Song W, Liu Y and
Huang L: Nanoformulated codelivery of quercetin and alantolactone
promotes an antitumor response through synergistic immunogenic cell
death for microsatellite-stable colorectal cancer. ACS Nano.
13:12511–12524. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Qian Y, Mao J, Leng X, Zhu L, Rui X, Jin
Z, Jiang H, Liu H, Zhang F, Bi X, et al: Co-delivery of
proanthocyanidin and mitoxantrone induces synergistic immunogenic
cell death to potentiate cancer immunotherapy. Biomater Sci.
10:4549–4560. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Jiang S, Wang S, Zhang L, Tian L, Li L,
Liu Z, Dong Q, Lv X, Mu H, Zhang Q and Wang B: Hesperetin as an
adjuvant augments protective anti-tumour immunity res ponses in
B16F10 melanoma by stimulating cytotoxic CD8+ T cells. Scand J
Immunol. 91:e128672020. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Lu R, Wang S, Jiang S, Li C, Wang Y, Li L,
Wang Y, Ma G, Qiao H, Leng Z, et al: Chrysin enhances antitumour
immunity response through the IL-12-STAT4 signal pathway in the
B16F10 melanoma mouse model. Scand J Immunol. 96:e131772022.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Zhang L, Wang S, Liu Z, Zhang L, Wang S
and Wang B: Procyanidin, a kind of biological flavonoid, induces
protective anti-tumor immunity and protects mice from lethal B16F10
challenge. Int Immunopharmacol. 47:251–258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Kang TH, Lee JH, Song CK, Han HD, Shin BC,
Pai SI, Hung CF, Trimble C, Lim JS, Kim TW and Wu TC:
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor
immunity induced by DNA vaccination. Cancer Res. 67:802–811. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Chuang CM, Monie A, Wu A and Hung CF:
Combination of apigenin treatment with therapeutic HPV DNA
vaccination generates enhanced therapeutic antitumor effects. J
Biomed Sci. 16:492009. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Olson DJ and Odunsi K: Adoptive cell
therapy for nonhematologic solid tumors. J Clin Oncol.
41:3397–3407. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Dudley ME and Rosenberg SA:
Adoptive-cell-transfer therapy for the treatment of patients with
cancer. Nat Rev Cancer. 3:666–675. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Du S, Yan J, Xue Y, Zhong Y and Dong Y:
Adoptive cell therapy for cancer treatment. Exploration (Beijing).
3:202100582023. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Chang YF, Chuang HY, Hsu CH, Liu RS,
Gambhir SS and Hwang JJ: Immunomodulation of curcumin on adoptive
therapy with T cell functiona limaging in mice. Cancer Prev Res
(Phila). 5:444–452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Nozhat Z, Heydarzadeh S, Memariani Z and
Ahmadi A: Chemoprotective and chemosensitizing effects of apigenin
on cancer therapy. Cancer Cell Int. 21:5742021. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Li M, Fan J, Hu M, Xu J, He Z and Zeng J:
Quercetin enhances 5-fluorouracil sensitivity by regulating the
autophagic flux and inducing drp-1 mediated mitochondrial
fragmentation in colorectal cancer cells. Curr Mol Pharmacol. Feb
27–2024.(Epub ahead of print).
|
|
206
|
Vazhappilly CG, Alsawaf S, Mathew S, Nasar
NA, Hussain MI, Cherkaoui NM, Ayyub M, Alsaid SY, Thomas JG, Cyril
AC, et al: Pharmacodynamics and safety in relation to dose and
response of plant flavonoids in treatment of cancers.
Inflammopharmacology. 33:11–47. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng
P, Chen A and Huang H: The fascinating effects of baicalein on
cancer: A review. Int J Mol Sci. 17:16812016. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Yang F, Song L, Wang H, Wang J, Xu Z and
Xing N: Quercetin in prostate cancer: Chemotherapeutic and
chemopreventive effects, mechanisms and clinical application
potential. Oncol Rep. 33:2659–2668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Mirazimi SMA, Dashti F, Tobeiha M, Shahini
A, Jafari R, Khoddami M, Sheida AH, EsnaAshari P, Aflatoonian AH,
Elikaii F, et al: Application of quercetin in the treatment of
gastrointestinal cancers. Front Pharmacol. 13:8602092022.
View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Dahiya A, Majee C, Mazumder R, Priya N and
Atriya A: Insight into the glycosylation methods of the flavonoids
as an approach to enhance its bioavailability and pharmacological
activities. Ind J Pharm Edu Res. 57:354–371. 2023. View Article : Google Scholar
|
|
211
|
Li C, Dai T, Chen J, Chen M, Liang R, Liu
C, Du L and McClements DJ: Modification of flavonoids: Methods and
influences on biological activities. Crit Rev Food Sci Nutr.
63:10637–10658. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Gopikrishna A, Girigoswami A and
Girigoswami K: Controlled drug delivery systems for improved
efficacy and bioavailability of flavonoids. J Achiev Mater Manuf
Eng. 116:49–60. 2023.
|
|
213
|
Naeem A, Ming Y, Pengyi H, Jie KY, Yali L,
Haiyan Z, Shuai X, Wenjing L, Ling W, Xia ZM, et al: The fate of
flavonoids after oral administration: A comprehensive overview of
its bioavailability. Crit Rev Food Sci Nutr. 62:6169–6186. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Bilia AR, Piazzini V, Risaliti L, Vanti G,
Casamonti M, Wang M and Bergonzi MC: Nanocarriers: A successful
tool to increase solubility, stability and optimise bioefficacy of
natural constituents. Curr Med Chem. 26:4631–4656. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Alizadeh SR, Savadkouhi N and Ebrahimzadeh
MA: Drug design strategies that aim to improve the low solubility
and poor bioavailability conundrum in quercetin derivatives. Expert
Opin Drug Discov. 18:1117–1132. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Pecorini G, Ferraro E and Puppi D:
Polymeric systems for the controlled release of flavonoids.
Pharmaceutics. 15:6282023. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Lee WH, Loo CY, Ong HX, Traini D, Young PM
and Rohanizadeh R: Synthesis and characterization of inhalable
flavonoid nanoparticle for lung cancer cell targeting. J Biomed
Nanotechnol. 12:371–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Loo CY, Traini D, Young PM, Parumasivam T
and Lee WH: Pulmonary delivery of curcumin and quercetin
nanoparticles for lung cancer-Part 1: Aerosol performance
characterization. J Drug Deliv Sci Technol. 86:1046462023.
View Article : Google Scholar
|
|
219
|
Hong L, Li W, Li Y and Yin S:
Nanoparticle-based drug delivery systems targeting cancer cell
surfaces. RSC Adv. 13:21365–21382. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Batool S, Sohail S, Ud Din F, Alamri AH,
Alqahtani AS, Alshahrani MA, Alshehri MA and Choi HG: A detailed
insight of the tumor targeting using nanocarrier drug delivery
system. Drug Deliv. 30:21838152023. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Chen D, Liu X, Lu X and Tian J:
Nanoparticle drug delivery systems for synergistic delivery of
tumor therapy. Front Pharmacol. 14:11119912023. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Xiao Z, Su Z, Han S, Huang J, Lin L and
Shuai X: Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint
and uses T cells to deliver NF-κB inhibitor for antitumor
immunotherapy. Sci Adv. 6:eaay77852020. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen
Y, Xiang G and Huang L: Curcumin micelles remodel tumor
microenvironment and enhance vaccine activity in an advanced
melanoma model. Mol Ther. 24:364–374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Tiwari P and Mishra KP: Role of
plant-derived flavonoids in cancer treatment. Nutr Cancer.
75:430–449. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Kadhum WR, Ramaiah P, Tayyib NA, Hjazi A,
Kahhharov AJ, Alkhafaji AT, Al-Dami FH, Ridha BM, Alsalamy AH and
Alwave M: Novel and potential therapy options for a range of cancer
diseases: Using flavonoid. Pathol Res Pract. Nov 29–2023.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Galati G and O'Brien PJ: Potential
toxicity of flavonoids and other dietary phenolics: Significance
for their chemopreventive and anticancer properties. Free Radic
Biol Med. 37:287–303. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Havsteen BH: The biochemistry and medical
significance of the flavonoids. Pharmacol Ther. 96:67–202. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Dong S, Guo X, Han F, He Z and Wang Y:
Emerging role of natural products in cancer immunotherapy. Acta
Pharm Sin B. 12:1163–1185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Khatib S, Pomyen Y, Dang H and Wang XW:
Understanding the cause and consequence of tumor heterogeneity.
Trends Cancer. 6:267–271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Xiao F, Farag MA, Xiao J, Yang X, Liu Y,
Shen J and Lu B: The influence of phytochemicals on cell
heterogeneity in chronic inflammation-associated diseases: The
prospects of single cell sequencing. J Nutr Biochem.
108:1090912022. View Article : Google Scholar : PubMed/NCBI
|
